GLP-1 Microdosing: What We Actually Know

Short answer: "microdosing" GLP-1 medications means using doses below the FDA-approved schedule, usually to reduce side effects or cost. It's a real, increasingly discussed practice, but it hasn't been studied in the large randomized trials that back standard dosing, so the weight-loss and safety data this calculator uses does not apply to microdosing.

Where the practice comes from

GLP-1 medications are already prescribed on a gradual dose-escalation schedule to reduce gastrointestinal side effects. "Microdosing" typically refers to staying at a lower dose for longer than the standard schedule, or using smaller increments than the approved pen or vial provides, often to stretch out a prescription or minimize side effects.

What the evidence actually supports

The weight-loss percentages reported in STEP 1 and SURMOUNT-1, the trials this calculator's estimates are based on, reflect people who followed the FDA-approved dose-escalation schedule up to a target maintenance dose. There isn't published randomized trial data showing what weight loss to expect at doses below that target, which means microdosing outcomes are largely anecdotal rather than evidence-based.

Why this matters before trying it

Any change to a prescribed dose or schedule, including staying below the target dose, should be discussed with the prescribing provider. Compounded or non-standard dosing also raises additional quality and safety considerations that don't apply to FDA-approved, pharmacy-dispensed doses.